1. For Gilead, its coronavirus treatment is icing on the cake— FDA considering virtual advisory panels but delays GSK, Intercept meetings — Sanofi in COVID-19 mRNA vaccine deal with Translate Bio — See more on our front page news Stay updated with the latest pharma-related coronavirus news on our new page
    Dismiss Notice
  2. Think you have witnessed fraud?Ask a Whistleblower Attorney -- a chance to discuss whistleblower-related legal issues with practicing whistleblower attorneys.
    Dismiss Notice

Dead product

Discussion in 'Otonomy' started by anonymous, Aug 5, 2016 at 9:48 AM.

Tags: Add Tags
  1. anonymous

    anonymous Guest

    Costs too much. No need, no data, no reimbursement. Team of 1000 sales representatives couldn't sell this.
     

  2. anonymous

    anonymous Guest

    true story
     
  3. anonymous

    anonymous Guest

    It's getting harder and harder to witness this much incompetence. How people are being promoted instead of being fired is beyond comprehension.
     
  4. anonymous

    anonymous Guest

    Pig with Lipstick
     
  5. anonymous

    anonymous Guest

    Costs too much. No need, no data, no reimbursement. Team of 1000 sales representatives couldn't sell this.
     
  6. anonymous

    anonymous Guest

    Costs too much. No need, no data, no reimbursement. Team of 1000 sales representatives couldn't sell this.
     
  7. anonymous

    anonymous Guest

    Costs too much. No need, no data, no reimbursement. Team of 1000 sales representatives couldn't sell this.
     
  8. anonymous

    anonymous Guest

     
  9. anonymous

    anonymous Guest

    How are sales with all 6 new reps? I bet the demand for the big O is at an all time high and payers are lining up to pay for it outside the bundle!!! Great work DK and Dino
     
  10. anonymous

    anonymous Guest

    Fire all 40 and hire 6 new ones?

    Brilliant.
     
  11. anonymous

    anonymous Guest

    This company should be renamed Lobotomy. It will make you brainless, like the people roaming the halls who are running the joint. If you come to this disaster, set your expectations low then be ready to be surprised to the downside.
     
  12. anonymous

    anonymous Guest

    Lobotomy will be insolvent soon
     
  13. anonymous

    anonymous Guest

    Vial sales must be huge as Dina continues to send her people into accounts to bring to light there is no reimbursment and gets them shut down. Great strategy.
     
  14. anonymous

    anonymous Guest

    I can't help but chuckle listening to this thread. Otonomy simply hired the wrong sales reps the first go around (Pharma reps aren't SALES reps). Now they have seasoned device reps averaging 6-10 years in the ENT space, who know their ENT surgeons personally, who know how to navigate a hospital, and who KNOW HOW TO CLOSE!!!

    Otonomy has a permanent J-code that is getting paid! All one has to do is set up the meeting with the hospital admin and the home office. This can only be done if you have the surgeons ear (PUN intended) and know who to go after in the hospital. Interesting that while its all Doom and Gloom from the previous regime Otonomy's stock price has gone from $13 to $19 just since May. They're doing more with 6 reps in 2 months than the previous 35 did all last year!

    MIC DROP!!!!
     
  15. anonymous

    anonymous Guest

    Cant wait to see the spin from Bernie on the next investors call!!
     
  16. anonymous

    anonymous Guest

    Maybe the 6 superstar device reps can reach half a million in sales in a whole quarter. Impressive.

    Everyone knows the stock price is being moved by Otiprio sales. The growth trajectory is out of this world. Of course it has nothing to do with the pipe dream they are selling on meniere's drug.

    Congrats Device pro's, you're now drug reps selling cipro and maybe a generic steroid. Good luck and everyone can't wait to see the numbers.
     
  17. anonymous

    anonymous Guest

    You device reps are killing it. I'm sure "tube season" is the reason right? You'll find out soon enough.

    first quarter (1,334 vials)
    second quarter (1,260 vials)

    We are only loser drug reps, but we can add, and that looks like a drop in vials. $0.3 million in sales, probably rounded up significantly, and cash dwindling.

    • Cash Position: Cash, cash equivalents, and short-term investments totaled $150.5 million as of June 30, 2017, compared to $196.4 million as of December 31, 2016.
    • Revenue: Net sales of OTIPRIO totaled $0.3 million for the second quarter of 2017 compared to $0.1 million for the second quarter of 2016.
    You guys sure are showing us, wow can you sell!
     
  18. anonymous

    anonymous Guest

    The leadership at this company is fucking Genius! Just wait till next quarter!! Bernie Madoff and his crew will spin the shit out of the $100K increase in sales of Oshitprio. And the new VP of sales, well what can I say, he is brilliant for convincing Bernie he could actually hire anyone to sell this overpriced generic.
    And Dino Lunch, lets not forget to recognize the real superstar in the bunch!! How anyone could even think about commercializing a product like Oshitprio deserves an honorable mention!
     
  19. anonymous

    anonymous Guest

    This is a textbook Ponzi scheme.
    Well executed on every level.
    Someone is going to become very wealthy.
     
  20. anonymous

    anonymous Guest

    Where did you see a 100k increase in sales? Sales went down quarter over quarter.